Modality
Vaccine
MOA
KRASG12Di
Target
MET
Pathway
Cell Cycle
MDD
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
~Nov 2018
→ ~Feb 2020
Phase 2
May 2020
→ Nov 2026
Phase 2Current
NCT03370757
1,117 pts·MDD
2020-05→2026-11·Terminated
1,117 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-137mo awayPh2 Data· MDD
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2026-11-13 · 7mo away
MDD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03370757 | Phase 2 | MDD | Terminated | 1117 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| DAW-5540 | Day One Bio | Phase 2 | AHR |